
ICLUSIG (ponatinib) offers convenient dosing in a single oral tablet1
Available in 45 mg, 30 mg, 15 mg, and 10 mg dosage strengths1
ICLUSIG is a single tablet taken orally once daily1
- Can be taken with or without food
- Tablets should be swallowed whole. Do not crush, break, cut, or chew tablets
- If a dose is missed, take the next dose at the regularly scheduled time the next day
ICLUSIG is available in multiple dosage strengths. Each dosage strength is available as a single oral tablet.1
Guidance for dose modifications
ICLUSIG (ponatinib) dose modifications
Recommended Dose Modifications for ICLUSIG for Adverse Reactions1
Based on CTCAE v5.0: Grade 1 mild, Grade 2 moderate, Grade 3 severe, Grade 4 life-threatening
ICLUSIG (ponatinib) dose reductions
Recommended Dose Reductions for ICLUSIG for Adverse Reactions1
ICLUSIG (ponatinib) dosage with strong CYP3A inhibitors
Recommended ICLUSIG Dosage for Coadministration of Strong CYP3A Inhibitors1
Dosing for patients with hepatic impairment
For patients with CP-CML, AP-CML, BP-CML, and Ph+ ALL receiving monotherapy, reduce the starting dose of ICLUSIG from 45 mg orally once daily to 30 mg orally once daily in patients with pre-existing hepatic impairment (Child-Pugh A, B, or C).
For patients with newly diagnosed Ph+ ALL, no dosage adjustment is recommended when administering ICLUSIG to patients with mild hepatic impairment (Child-Pugh A). Closely monitor patients with moderate or severe hepatic impairment (Child-Pugh B or C) and modify the ICLUSIG dosage in the event of adverse reactions.
Newly Diagnosed Ph+ ALL
EXPLORE DOSE REDUCTIONS OF ICLUSIG WITH CHEMOTHERAPY
ALT=alanine transaminase; ANC=absolute neutrophil count; AOE=arterial occlusive events; AP-CML=accelerated-phase chronic myeloid leukemia; AST=aspartate aminotransferase; BP-CML=blast-phase chronic myeloid leukemia; CP-CML=chronic-phase chronic myeloid leukemia; CTCAE=Common Terminology Criteria for Adverse Events; Ph+ ALL=Philadelphia chromosome-positive acute lymphoblastic leukemia; ULN=upper limit of normal; VTE=venous thromboembolic events.